Vanderbilt University Lowers Position in Boston Scientific Co. (NYSE:BSX)

Vanderbilt University trimmed its position in shares of Boston Scientific Co. (NYSE:BSX) by 28.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,681 shares of the medical equipment provider’s stock after selling 9,214 shares during the quarter. Vanderbilt University’s holdings in Boston Scientific were worth $2,115,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Czech National Bank boosted its position in shares of Boston Scientific by 7.1% during the third quarter. Czech National Bank now owns 299,989 shares of the medical equipment provider’s stock valued at $25,139,000 after purchasing an additional 19,833 shares in the last quarter. Miracle Mile Advisors LLC lifted its position in Boston Scientific by 4.0% during the third quarter. Miracle Mile Advisors LLC now owns 5,252 shares of the medical equipment provider’s stock valued at $440,000 after buying an additional 203 shares during the period. Atomi Financial Group Inc. boosted its holdings in shares of Boston Scientific by 13.7% during the 3rd quarter. Atomi Financial Group Inc. now owns 8,266 shares of the medical equipment provider’s stock valued at $693,000 after buying an additional 997 shares in the last quarter. Country Trust Bank purchased a new stake in shares of Boston Scientific in the 3rd quarter worth about $383,000. Finally, Brookstone Capital Management increased its stake in shares of Boston Scientific by 22.3% in the 3rd quarter. Brookstone Capital Management now owns 85,553 shares of the medical equipment provider’s stock worth $7,169,000 after acquiring an additional 15,608 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $104.95 on Thursday. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 12-month low of $64.08 and a 12-month high of $107.17. The firm has a market capitalization of $154.68 billion, a price-to-earnings ratio of 86.73, a price-to-earnings-growth ratio of 2.68 and a beta of 0.80. The firm has a 50 day moving average of $94.01 and a 200 day moving average of $86.71.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. On average, research analysts anticipate that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Wall Street Analyst Weigh In

BSX has been the topic of several research reports. Raymond James boosted their price objective on shares of Boston Scientific from $101.00 to $119.00 and gave the stock a “strong-buy” rating in a research note on Friday, January 31st. Morgan Stanley boosted their price target on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, October 24th. Citigroup raised their price objective on Boston Scientific from $98.00 to $107.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. TD Cowen boosted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein raised their price target on Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. One analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $100.39.

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now directly owns 978 shares of the company’s stock, valued at approximately $87,306.06. This represents a 93.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the transaction, the director now directly owns 39,398 shares in the company, valued at $3,610,038.74. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,302 shares of company stock valued at $4,464,725 over the last quarter. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.